Y-Mabs Therapeutics Inc (YMAB) is gearing up for another turning point as it hit the volume of 0.82 million

Y-Mabs Therapeutics Inc (NASDAQ: YMAB) on Monday, soared 9.53% from the previous trading day, before settling in for the closing price of $13.11. Within the past 52 weeks, YMAB’s price has moved between $2.70 and $14.07.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 38.80%. The company achieved an average annual earnings per share of 69.05%. With a float of $32.89 million, this company’s outstanding shares have now reached $43.67 million.

Y-Mabs Therapeutics Inc (YMAB) Insider Activity

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Y-Mabs Therapeutics Inc is 24.60%, while institutional ownership is 49.02%. The most recent insider transaction that took place on Dec 15, was worth 330,500. In this transaction Chief Business Officer of this company sold 50,000 shares at a rate of $6.61, taking the stock ownership to the 265,032 shares. Before that another transaction happened on Dec 14, when Company’s Chief Business Officer sold 50,000 for $6.83, making the entire transaction worth $341,500. This insider now owns 315,032 shares in total.

Y-Mabs Therapeutics Inc (YMAB) Earnings and Forecasts

As on 9/29/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.18 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.19) by $0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 69.05% per share during the next fiscal year.

Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Trading Performance Indicators

Y-Mabs Therapeutics Inc (YMAB) is currently performing well based on its current performance indicators. A quick ratio of 4.94 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.74.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.74 in one year’s time.

Technical Analysis of Y-Mabs Therapeutics Inc (YMAB)

Compared to the last year’s volume of 0.45 million, its volume of 0.55 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 73.52%. Additionally, its Average True Range was 0.92.

During the past 100 days, Y-Mabs Therapeutics Inc’s (YMAB) raw stochastic average was set at 98.67%, which indicates a significant increase from 97.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.57% in the past 14 days, which was lower than the 74.11% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $8.83, while its 200-day Moving Average is $6.97. Nevertheless, the first resistance level for the watch stands at $14.91 in the near term. At $15.46, the stock is likely to face the second major resistance level. The third major resistance level sits at $16.43. If the price goes on to break the first support level at $13.39, it is likely to go to the next support level at $12.42. Should the price break the second support level, the third support level stands at $11.87.

Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Key Stats

Market capitalization of the company is 626.38 million based on 43,622K outstanding shares. Right now, sales total 65,270 K and income totals -95,570 K. The company made 20,450 K in profit during its latest quarter, and -7,750 K in sales during its previous quarter.